We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current DNLI market cap is 3.07B. The company's latest EPS is USD -1.0090 and P/E is -21.06.
| Quarter End | Mar 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 35.14M | 0 | 0 | 0 | 0 |
| Operating Income | -120.82M | -132.57M | -132.25M | -116.59M | -123.19M |
| Net Income | -109.78M | -119.47M | -101.8M | -99.03M | -107.19M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M |
| Operating Income | -213.18M | 62.72M | -295.75M | -340.74M | -196.7M |
| Net Income | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M |
| Quarter End | Mar 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.41B | 1.15B | 1.58B | 1.5B | 1.45B |
| Total Liabilities | 442.64M | 122.96M | 125.62M | 115.51M | 135.52M |
| Total Equity | 966.71M | 1.03B | 1.46B | 1.39B | 1.32B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 553.23M | 1.6B | 1.4B | 1.46B | 1.15B |
| Total Liabilities | 158.34M | 453.75M | 441.87M | 417.81M | 122.96M |
| Total Equity | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B |
| Quarter End | Mar 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -58.8M | -357.99M | -113.62M | -204.84M | -263.98M |
| Investing | -92.72M | 249.31M | -453.19M | -354.62M | -260.96M |
| Financing | 1.6M | 17.82M | 500.28M | 507.03M | 488.47M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M |
| Investing | 147.71M | -623.21M | -21.63M | -141.39M | 249.31M |
| Financing | 6.19M | 634.75M | 19.35M | 310.67M | 17.82M |
| Market Cap | 3.07B |
| Price to Earnings Ratio | -21.06 |
| Price to Sales Ratio | 9.25 |
| Price to Cash Ratio | 24.06 |
| Price to Book Ratio | 2.97 |
| Dividend Yield | - |
| Shares Outstanding | 143.92M |
| Average Volume (1 week) | 1.15M |
| Average Volume (1 Month) | 1.02M |
| 52 Week Change | 10.59% |
| 52 Week High | 33.33 |
| 52 Week Low | 14.56 |
| Spread (Intraday) | 0.02 (0.09%) |
| Company Name | Denali Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.denalitherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
